

**Form 51-102F3**  
**Material Change Report**

**1. Name and Address of Company**

**Enttheon Biomedical Corp. (formerly, MPV Exploration Inc.)**  
Suite 720 - 999 W Broadway Street  
Vancouver, BC  
V5Z 1K5  
(the "Company")

**2. Dates of Material Change(s)**

March 15, 2022

**3. News Release(s)**

News release was issued on March 15, 2022 and disseminated via Stockwatch pursuant to section 7.1 of National Instrument 51-102.

**4. Summaries of Material Changes**

The Company announces that it has filed a final short form base shelf prospectus (the "**Final Prospectus**") with the securities commissions in each of the provinces and territories of Canada.

**5. Full Description of Material Changes**

News Release dated March 15, 2022— See Schedule "A".

**6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**7. Omitted Information**

No information has been omitted.

**8. Executive Officer**

Mr. Timothy Ko, President, CEO and Director of the Company, is knowledgeable about the material change contained herein and may be reached at (604) 562-3932.

**9. Date of Report**

This report is dated March 16, 2022

## Entheon Biomedical Corp. Files Final Shelf Prospectus

Vancouver, BC – March 15, 2022 – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("**Entheon**" or the "**Company**") announced today that it has filed a final short form base shelf prospectus (the "**Final Prospectus**") with the securities commissions in each of the provinces and territories of Canada.

The Final Prospectus filing allows Entheon to make offerings of common shares, warrants, units, subscription receipts and/or debt securities up to an aggregate total of Cdn\$75 million during the 25-month period that the Final Prospectus remains effective. Such securities may be offered in amounts, at prices and on terms to be determined based on market conditions at the time of sale and set forth in one or more shelf prospectus supplement(s) and, subject to applicable regulations, may include at-the-market transactions, private placements, public offerings or strategic investments. Information regarding the use of proceeds from a sale of such securities will be included in the applicable prospectus supplement.

Copies of the preliminary short form base shelf prospectus and Final Prospectus, as well as any shelf prospectus supplements that may be filed in the future, can be found on the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com) or may be obtained by request to the Chief Financial Officer of Entheon, at Suite 720 – 999 West Broadway Vancouver, British Columbia, V5Z 1K5, Telephone (604) 351-6437.

If any securities are offered under the Final Prospectus, the terms of any such securities and the intended use of the net proceeds resulting from such offering would be established at the time of any offering and would be described in a prospectus supplement filed with the applicable Canadian securities regulatory authorities at the time of such an offering and would be made available by Entheon at the above address.

### **About Entheon Biomedical Corp.**

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N,N-dimethyltryptamine based psychedelic therapeutic products ("**DMT Products**") for the purposes of treating addiction and substance use disorders. Entheon is comprised of three divisions, Entheon RX™, focused on the development of therapeutic drugs, using DMT as the pharmacological benchmark; Entheon ID™, focused on identification, analysis and predictive use of EEG biomarkers and genetics in the selection and management of drug treatment; and Entheon IQ™, focused on the development of treatment algorithms through the analysis of patient data. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.

**On Behalf of the Board of Directors,  
Timothy Ko, CEO, President and Director**

**For more information, please contact the Company at:**

**Entheon Biomedical Corp.**

Joseph Cullen, Investor Relations

Telephone: +1 (778) 919-8615

[joe@entheonbiomedical.com](mailto:joe@entheonbiomedical.com)

<https://entheonbiomedical.com/>

**For media inquiries, please contact David Mayoh, Communications Manager at:**

**David Mayoh, Communications Manager**

Telephone: +1 (780) 777-8738

[david@entheonbiomedical.com](mailto:david@entheonbiomedical.com)

*This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including in the United States.*